Phase 2 Imlifidase Trial Shows Positive Results in Treating Goodpasture’s Disease
Near the end of September, Hansa Biopharma ("Hansa") announced promising data from a Phase 2 clinical trial on imlifidase. This therapy is designed to treat patients with severe anti-GBM antibody…